→ A little more than two years ago, Bristol-Myers agreed to ante up $50 million to get an option on F-star’s experimental cancer drug for HER-2 positive cancers. But now we learned that the biotech giant is taking a pass on that deal, abandoning a set of potential payouts that rang in at $475 million. The drug, FS102, is now wrapping a Phase I dose-ranging study. John Haurum, CEO of F-star, commented: “Our productive relationship with Bristol-Myers Squibb has generated valuable clinical data supporting the low immunogenic potential of Fcabs, as well as a favourable pharmacokinetic profile comparable to traditional antibodies. The decision by Bristol-Myers Squibb has no impact on the development of our own pipeline and our focus on development of bispecific antibodies in the area of immuno-oncology. We appreciate the challenges of developing therapeutics in the highly-competitive HER2 space, which we are factoring in to our assessment of how to best proceed with the FS102 programme.”
→ Zymeworks has priced its IPO at $13, raising $59 million for the company. That’s the low end of the range. A string of biotechs are maneuvering into the public market this month, marking a distinct uptick in IPO activity.
→ The China Food and Drug Administration has approved Bristol-Myers combo of Daklinza (daclatasvir) and Sunvepra (asunaprevir) for hep C.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 28,000+ biopharma pros who read Endpoints News by email every day.Free Subscription